Liposome Circulation Time is Prolonged by CD47 Coating. by Hayat, SMG et al.
Hayat, SMG, Jaafari, MR, Hatamipour, M, Penson, P and Sahebkar, A
 Liposome Circulation Time is Prolonged by CD47 Coating.
http://researchonline.ljmu.ac.uk/id/eprint/12880/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research.
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Hayat, SMG, Jaafari, MR, Hatamipour, M, Penson, P and Sahebkar, A (2020) 
Liposome Circulation Time is Prolonged by CD47 Coating. Protein & 





Liposome circulation time is prolonged by CD47 coating 
 




1Department of Medical Biotechnology, Faculty Medicine, Mashhad University of Medical 
Sciences, Mashhad, Iran 
2Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of 
Medical Sciences, Mashhad, Iran 
3Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of 
Medical Sciences, Mashhad, Iran 
4School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, 
UK 
5Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, 
Iran 
6School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran 
 
Correspondence: 
 Amirhossein Sahebkar, Department of Medical Biotechnology, School of Medicine, Mashhad 
University of Medical Sciences, Mashhad, Iran, P.O. Box: 91779-48564, Iran; Tel: 985118002288; Fax: 
985118002287; E-mail: sahebkara@mums.ac.ir; amir_saheb2000@yahoo.com  
 
 Mahmoud Reza Jaafari, Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad 
University of Medical Sciences, Mashhad 91775-1365, Iran.   
 
Running title: CD47-decorated liposomes with prolonged half-life 
 
 
Source of funding: This project was financially supported by the Mashhad University of Medical 
Sciences Research Council (Mashhad, Iran). The project was also supported by a grant from cancer 
research center of cancer institute of Iran (Sohrabi cancer charity, Grant No: 37652-202-01-97) 
and a Grant No. 961204 of the Biotechnology Development Council of the Islamic Republic of 
Iran. 
 
Availability of data and material: Data associated with this article are available from the 





Seyed Mohammad Gheibi Hayat (https://orcid.org/0000-0002-1378-118X) 
Mahmoud R. Jaafari (https://orcid.org/0000-0003-3908-6828) 
Mahdi Hatamipour (https://orcid.org/0000-0002-0782-1907) 
Peter E. Penson (https://orcid.org/0000-0001-6763-1489) 






4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
Antibody against PEG (antiPEG) 
Area Under the Curve (AUC) 
Area Under the Momentum Curve (AUMC) 
Artificial Antigen Presenting cells (aAPC) 
Clearance (Cl) 
Concentration Maximum (CM) 
Dimethyl Sulfoxide (DMSO) 
Doxorubicin Hydrochloride (Dox)  
Food and Drug Administration (FDA) 
High Performance Liquid Chromatography (HPLC) 
Human Monocyte Cell Line (THP-1) 
Hydrogenated Soya Phosphatidylcholine (HSPC) 
Layer Chromatography (TLC) 
Liposomal Doxorubicin (LD) 
Mean Residence Time (MRT) 
Methoxypolyethyleneglycol (Mw 2000)-distearylphosphatidylethanolamine (mPEG2000-DSPE) 
Mononuclear Phagocytic System (MPS) 
Nuclear Magnetic Resonance (NMR) 
Pegylated Liposomal Doxorubicin (PLD) 
Polyethylene glycol (PEG) 
Polyethylene Glycol–polylactic Acid (PEG–PLA) 
Red Blood Cells (RBC) 
Reticuloendothelial System (RES) 
Self Peptide (SP) 
Self peptide Liposomal Doxorubicin (SP-LD) 







Bio-degradable nano-particles have many applications as drug delivery vehicles because of their good bio-
availability, controlled release, low toxicity and potential for encapsulation. However, the most important 
obstacle to nanoparticulate drug delivery is elimination by macrophages which reduces the residence time 
of nanoparticles in the blood. To overcome this problem, the surface of the nanoparticle can be passivated 
by coating with Polyethylene glycol (PEG). However, the use of PEG has its own disadvantages. CD47 
receptor acts as a self marker on the surface of many cells and inhibits phagocytosis. This study used a 




Doxorubibin was used as a model drug because of its inherent fluorescence. Doxorubicin-containing 
liposomes were coated with different percentages of CD47 mimicry peptide (0.5% and 1%). PEG-
functionalized doxorubicin-containing liposomes, were used as a comparator. The liposomal formulations 
were intravenously injected into mice. Serum was collected at pre-defined time points and tissue samples 
were taken at 24 hours. Fluorescence was used to determine the concentration doxorubicin in serum,  heart, 
spleen, kidney, liver and lung tissues.  
 
Results 
Tissue biodistribution and serum kinetic studies indicated that compared with PEG, the use of CD47 
mimicry peptide increased the circulation time of doxorubicin in the circulation. Moreover, unwanted 
accumulation of doxorubicin in the reticuloendothelial tissues (liver and spleen), kidney and heart was 
significantly decreased by the CD47 mimicry peptide. 
 
Conclusion 
The use of a CD47 mimicry peptide on the surface of nanoliposomes improved the residence time of 
liposomal doxorubicin in the circulation. The accumulation of drug in non-target tissues was reduced, 
thereby potentially reducing toxicity.  
 
 










The unique properties of nanoparticles allow them to be used to deliver drugs to a wide range of tissues in 
the human body. The encapsulation of hydrophobic drugs, nucleic acids and proteins in nano-particles is 
increasingly employed as a technique to reduce intra-cellular degradation, increase the circulation time and 
enhance the therapeutic effects of the molecule being delivered. Liposomes, discovered for the first time 
by Alee Bangham in 1963 [1], are the most studied nanostructures in drug delivery. Liposomes have unique 
properties such as biocompatibility, biodegradability, delivery capacity for both hydrophilic and 
hydrophobic cargos and low immunogenicity and toxicity, leading to their widespread use in drug delivery 
[2]. 
Rapid uptake of nanoparticles by circulating macrophages is the biggest obstacle to their use in drug 
delivery. Macrophages are leukocytic cells that can phagocytize or absorb cellular debris, bacteria, and 
particles by an energy-consuming process of membrane engulfation. Macrophages play an important role 
in the initial response of the body to the presence of potentially harmful foreign materials [3]. Macrophages 
substantially affect the tissue distribution of nanoparticles and their residence time in the blood. Moreover, 
macrophages can induce unwanted inflammatory responses, and interfere with the treatment process. In 
tissues, particularly in the filtration organs (liver, kidney, spleen, and lung) the mononuclear phagocytic 
system (MPS) actively clears nanoparticles  [4-8]. It has been demonstrated that filtration organs sequester 
about 95% of systemically delivered nanoparticles [9, 10]. Therefore nanomaterial-based drug delivery is 
limited by rapid clearance from blood and target delivery sites, and inflammatory responses which are 
initiated when nanoparticles accumulate in macrophages in the clearance organs [11-16].  
 
The absorption and phagocytic degradation of nano-materials may be reduced by altering the 
physicochemical properties of the particle surface e.g surface energy, hydrophobicity, hydrophilicity and 
the presence of steric obstacles such as the grafted polymer brush surface. The hydrophilic molecule, 
poly(ethylene glycol) (PEG) has been used in a variety of settings to provide a brush-like steric obstacle. 
This reduces protein absorption and is associated with longer blood circulation times for a number of 
particles [17]. Doxil®, Pegylated liposomal doxorubicin (PLD), is the first nano-medicine delivery system 
to have been accepted by FDA, and is based on PEGylated liposomes [18]. NK911 is a DOX-encapsulated 
micelle from a co-polymer of PEG-DOX-conjugated poly(aspartic acid). Genexol-PM is a paclitaxel-
encapsulated PEG-PLA micelle formulation that has received approval for clinical use [19]. Nevertheless, 
pegylation has some disadvantages and complications. PEG is a large molecule, its existence on the nano-
particle (or liposomal) surface can inhibit the interaction of nanoparticles (or liposomes) with cells, and 
hinder the introduction of liposomes into target cells [20]. Repeated administrations of the PEGylated 
formulation may speed up their clearance from the blood. It is often argued that PEG is non-antigenic and 
weakly immunogenic, however the existence of a naturally occurring antibody against PEG (antiPEG) was 
first demonstrated in 1983 and is relatively common. The antibody has been characterized in animal models. 
Furthermore, some data have quetioned the usefulness of PEGylation in increasing the circulation time of 
nanoparticles (or liposomes) in the blood [21-24].  
 
Therefore, new approaches which do not rely upon PEGylation are required to enhance the bioavailability 
of drugs carried by liposomes and nanoparticles. CD47 is a protein found on the surface of red blood cells 
(RBC), which sends a "Don't eat me" message when it is exposed to the SIRPα receptor on the surface of 
macrophages. CD47 thereby prevents phagocytosis of the RBCs by macrophages. Interestingly, cancer cells 
transmit the "Don't eat me" signal to the macrophages by expressing the CD47 protein on their surface and 
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thus defend themselves against the risk of phagocytosis by macrophages [25] . Therefore, it is possible to 
transmit the "Don't eat me" signal to the macrophages using the CD47 protein on the nanoliposomes surface, 
and to reduce or prevent the clearance of nanoliposomes by macrophages. Because of the large size of 
CD47, this study employed a CD47 mimicry protein (Self peptide: SP) instead. Doxorubicin was loaded 
into nanoliposomes so that it could easily be traced in serum and tissue by virtue of its autofluorescence. 
This research experimented if it is possible for SP-coated liposomes to reduce phagocytic absorption by 
macrophages compared with PLD uptake. 
2. Materials and methods 
2.1 Materials 
China Peptides Co. (Shanghai: China) performed the synthesis of SP (cgggCERVIGTGWVRC) which had 
a molecular weight of 1.69 KD and 95.08% purity. Cholesterol, doxorubicin hydrochloride (Dox) and 
Dowex® 50WX4-400 were obtained from Sigma–Aldrich (St. Louis: MO).  Methoxypolyethyleneglycol 
(Mw 2000)-distearylphosphatidylethanolamine (mPEG2000-DSPE) and hydrogenated soya 
phosphatidylcholine (HSPC) were supplied by Lipoid (Ludwigshafen: Germany). Acidified isopropyl 
alcohol (90% isopropanol/0.075 M HCl) was produced by the addition of 2.5 mL water and 7.5 mL HCl 1 
M to 90 mL isopropanol (Merck; Darmstadt: Germany). Doxil® was obtained from Behestan Darou 
Company (Tehran, Iran). 
  
2.2 Conjugation of the CD47 mimicry peptide to PEG2000-DSPE-Mal 
The variables listed below were used to calculate the number of peptide molecules in each liposome. 1. 
Phospholipid concentrations of Doxil; 13.279 mM, 2. Average diameter of liposomes; 100 nm, 3. Lipid 
molecules/liposome with the average size of 100 nm; 8 × 104, 4. The number of liposome/ml: 1 × 1014, 5. 
Total contents of peptide; 0.4 mM, 6. The number of peptide molecules/ml aliquot of peptide-micelle; 2.4 
× 1014, 7. Number of peptides/liposome (150 & 300 ligand). Thioether linkage between thiol groups of 
cysteine residue was used to synthesize the peptide conjugation with DSPE-PEG2000-Mal. Mixing of the 
peptide (dissolved in dimethyl sulfoxide, DMSO) and maleimide-PEG2000-DSPE (dissolved in 
chloroform) was performed at molar ratios of 1:1. The mixture was exposed to argon gas in order to 
eliminate chloroform. The volume of the mixture was adjusted to 1 mL by the addition of HEPS buffer 
pH=7.2 (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). The ligation reaction was then performed at 
37 ˚C for 24 hours. 
 
2.3 Determination of peptide coupling efficiency 
The extent of peptide coupling to the surface of the liposome was determined using three methods: Thin 
Layer Chromatography (TLC), High Performance Liquid Chromatography (HPLC) and Nuclear Magnetic 
Resonance (NMR). 
 
2.4 Preparation of liposomes 
The extrusion method and thin-film hydration were used to prepare the liposome formulation. Remote 
loading, using the ammonium sulfate gradient method [26], was employed to encapsulate Dox in the 
liposomes. The liposome nomenclature and lipid compositions are shown in Table 1.  
Briefly, appropriate quantities of lipids in chloroform solution were mixed in round-bottom flasks.  Solvent 
removal was achieved using a vacuum-equipped rotary evaporator and freeze-drying. Pre-warmed 
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ammonium sulfate (250 mM) was used to hydrate the final thin films to achieve total lipid concentration of 
50 mM. Sonication was performed at 60°C for fifteen minutes under an argon atmosphere. The sonicated 
suspension was then passed across poly-carbonate nano-pore filters with pore sizes of 50, 100, 200, and 
400 nm (Avestin: Canada). The external medium was substituted with HEPES buffered sucrose (HBS: 10 
mM HEPES; 300 mM sucrose; pH=7.0) by dialysing the cassettes (Pierce: Rockford; IL) with 12–14 kDa 
molecular weight cut off (MWCO). To achieve optimal temperatures for DOX loading, incubation of 
aliquots (0.2 ml) of liposomes was initially performed with DOX hydrochloride (1 mg DOX/7 µmol total 
phospholipid) at 20, 30, 40, 50, 60, and 70°C for 60 minutes, and left to cool to room temperature. Aliquots 
of 25 µl were transferred to vials with 40 mg of Dowex resin and 1 ml of 10% sucrose (w/v) to remove the 
un-encapsulated DOX. 
 
2.5 Liposome characterisation  
A Dynamic Light Scattering (DLS) instrument (Nano-ZS; Malvern, UK) was used to characterize 
liposomes in terms of the size, zeta-potential, and poly-dispersity index. The phospholipid content was 
measured using a method based on the Bartlette phosphate assay. Spectrofluorimetry (ex: 470 nm/em: 590 
nm, PerkinElmer LS45) was used to measure the concentration of DOX in liposomes by comparison with 
a calibration curve produced from DOX in acidified isopropanol. This procedure included the addition of 
25 µl of the liposomes to vials with 40 mg of 1 ml of 10% sucrose (w/v) and Dowex resin, which was stirred 
for 1 min. Afterwards, dissolution of 0.1 ml of the supernatant was performed in 2 ml of the acidified 
isopropanol (90% isopropanol/0.075 M HCL). Then, the DOX fluorescence of the solution was measured. 
Likewise, a spectrofluorometer (ex: 600 nm/em: 665 nm) was used to measure the Dox content of liposomes 
in acidified isopropanol. It should be noted that the Dox concentration was determined before and after 
purification in order to determine the encapsulation efficacy of DOD. The formula below was used to 
calculate the proportion of Dox encapsulated: 
%𝐷𝑜𝑥 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 =
Dox encapsulation after purification
Dox encapsulation before purification
 ×100 
 
2.6 Measurement of cellular uptake 
Cellular uptake of all liposomal formulas was examined in the J774.1 cell line. The cells were seeded into 
24-well plates at cell densities of 100,000-200,000 cells/well on the 1st day. On the 2nd day, the cell medium 
was removed. All liposomal formulas were mixed with growth medium which was added to the plates at a 
normalized DOX concentration of 10 μM (5 μg/mL).  The plates were  incubated at 37 °C for 24 h. No drug 
was added to the control group wells. The cell medium was eliminated after 24 h, and ice-cold PBS (pH 
7.0) was used to wash the cells 4 times. The cells were then lysed with 1 mL of DMSO. Centrifugation of 
the supernatants was performed at 140,000 rpm for 10 min, and the supernatants were gathered to obtain 
the cell lysates. A spectro-fluorometer at λex = 496 nm, λem = 592 nm to was used to measure the DOX 
fluorescence intensity of the cell lysates in order to calculate the DOX concentration. The mean (± SD) of 
3 wells in all treatments for all experiments was used to calculate the intracellular uptake of DOX. 
 
2.7 Bio-distribution  
Mice (balbC) with an average weight of 25 to 30 g and about four weeks old were purchased from the 
Pasteur Institute of Iran (Tehran, Iran) and were kept with ad libitum access to food and water. The Ethics 
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Committee for Animal Experiments of the Mashhad University of Medical Sciences gave approval for all 
experimental protocols involving animals . 
 
Mice were categorized into four groups (four mice in each group) for bio-distribution. The injection of all 
liposomal formulations was performed through the tail vein in a single dose (15 mg/kg doxorubicin 
equivalent) of either LD, 0.5%SP-LD, 1%SP-LD, or PLD formulations (equivalent volumes of 
approximately 200 uL of dextrose 5%). Contol mice received 200 uL of dextrose 5%. 
 
Retro-orbital bleeding (~0.5 mL) was used to collect  blood samples at three and six hours after dosing. The 
mice were killed to harvest tissue at 24 hours. Heart puncture was performed in order to collect the blood 
sample. Sdditionally, spleen, lungs, kidneys, heart, and parts of the liver were dissected, weighed, and 
placed in  2 mL polypropylene microvials (Biospec; OK) containing 1 mL of the acidified isopropanol and 
zirconia beads. MiniBeadbeater-1 (Biospec; OK) was then used to homogenize tissue. Blood was left to 
coagulate at 4˚C and was centrifuged for ten minutes at 14,000 rpm. At the next step, the serum was isolated, 
and dilution of a sufficient volume was done in 1 mL acidified isopropanol. The homogenized tissue 
samples and sera were maintained at 4 ˚C overnight to extract the drug. The samples were then centrifuged 
and the supernatant was assayed to measure concentration of Dox spectro-fluorimetrically (Ex; 470 nm; 
Em = 590 nm). Serial dilutions of Dox in tissues and sera extracts of the control mice were used to prepare 
the calibration curve. 
 
2.8 Pharmacokinetics 
Centrifugation of the blood samples was performed immediately at 1078 g for ten minutes to obtain plasma. 
The concentration of Dox was then measured in different groups. The mean residence time (MRT) was 
calculated by dividing the area under the curve (AUC) by the area under the momentum curve (AUMC). 
PK solver ADD-IND in Excel Microsoft was used to calculate the pharmacokinetic variables [27]. 
 
2.8 Statistical analyses 
GraphPad Prism5 (GraphPad Software; San Diego: CA) was used to perform statistical analyses. The level 
of doxorubicin concentration in spleen, plasma, lung, heart, liver, and kidney is provided as the 
concentration value (written as mg of drug or metabolite/ml of plasma or gram of tissue). Each value is 
written as the mean+SEM. Analysis of variance, Bartlett, and Student–Newman–Keuls tests were used to 
compare experimental groups. 
3. Results 
3.1 Peptide coupling efficiency 
The results of TLC, HPLC and NMR showed the formation of thioether bond between the cysteine 
(available at end of the peptide) and maleimide (available in DSPE-PEG (2000) Maleimide) (Data not 
shown). 
 
3.2 Liposome characterisation  
The particle diameter of the liposomes was about 110 nm (Polydispersity index <0.09) in all groups, and 




The efficiency of Dox encapsulation of each preparation was more than 96%. Leakage stability experiments 
did not indicate a significant difference in the release of Dox from peptide-modified or non-modified 
liposomes during 48 h incubation at 37˚C in the presence of 30% FCS. Liposomes showed the least Dox 
leakage, and more than 90% of the encapsulated Dox remained encapsulated.  
 
3.3 Cellular uptake of Dox 
Phagocytosis was 18% lower in the 1%SP-LD compared with the PLD group, showing a significant 
difference between the two groups (P<0.05). Furthermore, phagocytosis was significantly different between 
the  0.5%SP-LD group and the 1%SP-LD group (P<0.05). However, there was no significant difference 
between PLD and 0.5%SP-LD groups (Figure 1). 
  
3.4 Bio-distribution of Dox 
Biodistribution of  each liposomal formulation was estimated by gauging intrinsic autofluorescence signals 
of doxorubicin in spleen, liver, kidney, heart, and lung in mice (Figure 2). Doxorubicin accumulation was 
significantly reduced in most tissues in the 1%SP-LD group. 
 
2.5 Pharmacokinetics 
The results obtained from the biodistribution of BalbC mice (Figure 3) show that the content of serum 
doxorubicin at 0.5 h after injection was significantly different between the SP-LD and PLD groups and LD 
group. However, there was no significant difference among 0.5%SP-LD, 1%SP-LD, and PLD groups. 
Although there was no significant difference between 0.5%SP-LD and PLD at 6 h after injection, a 
significant difference was reported between 1%SP-LD and PLD. In addition, there was a significant 
difference between 0.5%SP-LD and 1%SP-LD. The difference between the groups was more substantial at 
24 h after injection. The concentration of doxorubicin in the serum of the 1%SP-LD group was nearly 
double that of the PLD group. 
 
Table 2 presents other pharmaco-kinetic parameters such as area under the curve (AUC), concentration 
maximum (CM), mean residence time (MRT), clearance (Cl), and half-life ,t1/2. 
4. Discussion 
Much progress has been made in the field of nanotechnology and liposomal drug delivery for the treatment 
of various diseases [28-31]. Using functional ligands like CD47 coud be an appropriate strutegy to 
overcome drug delivery limitations with liposomes [32]. 
The CD47 protein is found on the surface of most cells in the body, and contributes to apoptosis, 
proliferation, adhesion, homeostasis, and cell migration. One of the most important roles of CD47 protein 
is to transmit the "Don't eat me" signal through the SIRPα ligand on the macrophage membranes. The 
present study used the CERVIGTGWVRC peptide sequence as a Self-Peptide (SP) on the surface of 
liposomes. This process aims to prevent liposomal clearance by macrophages via transmitting the "Don't 
eat me" signal to macrophages. Results obtained from HPLC and NMR demonstrated that the SP is well 
linked to DSPE-PEG (2000) Maleimide. In vitro results also showed that the use of the CD47 mimicry 
peptide prevents phagocytosis in macrophages. Moreover, in vivo results demonstrated that if SP-LD is 
used, this will result in a longer residence time in the blood circulation, as compared to PLD. Furthermore, 
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SP-LD accumulation was much lower in liver, spleen and lung tissues. This likely reduces the severity of 
side effects, which occur when nanoparticles containing drugs accumulate in non-target tissues. 
 
Tissue biodistribution results in different tissues revealed that there is a significant difference between SP-
LD and PLD in liver, spleen, and lung tissues. Greater accumulation of PLD was observed in these tissues. 
For example, doxorubicin concentrations in spleen tissue were 40% lower in the 1%SP-LD group compared 
to the PLD group. The same comparison for the liver tissue indicated that the level of doxorubicin in the 
1%SP-LD group declined by 36% compared to the PLD group. This phenomenon occurred because the 
tissue macrophages in the RES system, result in greater absorption and uptake of the PLD form in these 
tissues. However, since phagocytosis is inhibited by SP, the SP-LD form undergoes much less phagocytosis 
and uptake into RES tissues. 
 
These antiphagocytotic effects are consistent with results reported by Tasi et al. who used biotin and 
streptavidin, and linked CD47 to the polystyrene beads. These CD47-coated beads were then exposed to 
the human monocyte cell line (THP-1). The researchers observed that the rate of phagocytosis was reduced 
by 50% compared to the control sample (polystyrene without CD47) [33]. Moreover, Bruns et al. (2015) 
observed antiphagocytic effects  of the CD47 receptor in artificial antigen-presenting cells (aAPC). These 
authors succeeded in designing a "don't eat me" aAPC using CD47-Ig on a classical aAPC [34]. 
 
Increasing the residence time of SP-LD in the circulatoin due to the inhibition of macrophage phagocytosis 
may allow achieving better therapeutic outcomes. For example, T1/2 value for 1%SP-LD(Ct=24=8.86) 
increased by about 29% in comparison to PLD(Ct=24=6.86) formulation. Moreover, the clearance rate of 
1%SP-LD (0.0077) formulation decreased by 25% compared to PLD(0.0102), representing a slower 
removal of 1%SE-LD formulation of the blood circulation compared to the PLD formulation. Additional 
pharmacokinetic parameters such as ACU and MRT showed that SE-LD clearly outperforms PLD. The 
results of this study demonstrate that this SP may defend LD against phagocytic activity of macrophages, 
and improve  in-vivo pharmacokinetics and tumor distribution. This research used 150 and 300 peptides on 
0.5%SP-LD and 1%SP-LD formulations, respectively. Comparison between the two groups indicated more 
acceptable effects with use of 300 peptides compared 150 peptides. The theoretical SP density on liposomes 
is of a similar order of magnitude (350 molecules/mm2) to the observed physiologic situations on human 
red blood cells (250 molecules/mm2) (20299253). 
 
5. Conclusion 
One of the most important problems associated with nanoparticle-based drug delivery is the rapid removal 
of nanoparticles by macrophages in the circulating blood, and the consequent short residence time of drug-
carrying nanoparticles. A deep understanding of the interaction between macrophages and nanoparticles in 
can be used to improve drug delivery strategies. The interaction between the CD47 receptor and SIRPα (on 
the macrophage membrane) is very important because it inhibits phagocytosis by transmitting a message to 
the macrophages. The use of the CD47 receptor mimicry peptides on the nanoparticles’ surface can inhibit 
phagocytosis by macrophages, and increase the residence time of nanoparticles in the circulation. Increasing 
the residence time of nanoparticles containing drug in the blood circulation may improve the efficacy of 
treatment. Our results suggest that CD47 coating reduces the accumulation of nanolipsomes in the tissues, 
which can reduce the risk of off-target toxicty of drugs in non-tumor tissues. Future stuidies are warranted 
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to confirm the present findings using other drugs and tumor models. Moreover, detailed toxicological 
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Figure 1.   24-hour intra-cellular Dox uptake in J774.1 cells (n=3 experiments, 3 wells/treatment. 
Abbreviations: LD: Liposomal Doxorubicin, PLD: Pegylated Liposomal Doxorubicin, SP-LD: Self Peptide 





Figure 2. Concentrations of DOX in tissues at 24 h after injection of LD, PLD, 0.5%SP-LD, and 1%SP-
LD at the equivalent DOX concentration of 15 mg/kg. Data are shown as mean ± standard deviation (n = 
4). *indicates signifcant diferences (p < 0.01) 
Abbreviations: LD= Liposomal doxorubicin. PLD= Pegylated liposomal doxorubicin.  SP-LD= Self 
peptide liposomal doxorubicin. 
 
 
Figure 3. Plasma concentration of DOX (at 3 time points (3,6, & 24 h) after administration of LD, PLD, 
0.5%SP-LD, and 1%SP-LD at the equivalent DOX concentration of 15 mg/kg.. Data are shown as mean ± 
standard deviation (n = 4). *indicates signifcant diferences (p < 0.01). 
14 
 
Abbreviations: LD= Liposomal doxorubicin. PLD= Pegylated liposomal doxorubicin.  SP-LD= Self 






















Table 1. Physical features of various formulations of liposome. Each value represents means ± SD (n=3). 
Liposome Liposome composition (molar ratio) Z-average size (nm) Pdia 
LP HSPC, Chol (62: 38) 107 ± 0.9 0.01 ± 0.01 
PLD HSPC, Chol, mPEG2000-DSPE (61.5: 38: 0.5) 110 ± 1.1 0.12 ± 0.02 
0.5%SP-LD HSPC, Chol, pept-mPEG2000-DSPE (61.5: 38: 0.5) 113 ± 1.2 0.05 ± 0.03 
1%SP-LD HSPC, Chol, pept-mPEG2000-DSPE (61: 38: 1) 112 ± 1.5 0.09 ± 0.04 
 
a Values are written as the mean±SD of 3 independent liposome samples (n=3). 
b Poly-dispersity index (PDI) 
Abbreviations: LD: Liposomal Doxorubicin, PLD: Pegylated Liposomal Doxorubicin, SP-LD: Self Peptide 
Liposomal Doxorubicin, SP-PLD: Self Peptide Pegylated Liposomal Doxorubicin 
 
 
Table 2. Plasma pharmacokinetic variables after the  intravenous injection of 15 mg/kg of LD, PLD, 0.5%SP-LD, and 













LD 85.01 1000 0.0139 6.60 6.82 
PLD 113.52 1349 0.0102 7.00 6.86 
0.5%SP-LD 114.58 1434 0.0091 9.43 8.34 
1%SP-LD 120.1 1668 0.0077 10.83 8.86 
a Concentration Maximum, b Area Under Curve, c Clearance, d Mean Residence Time, e Half life 
Abbreviations: LD: Liposomal Doxorubicin, PLD: Pegylated Liposomal Doxorubicin, SP-LD: Self Peptide 
Liposomal Doxorubicin, SP-PLD: Self Peptide Pegylated Liposomal Doxorubicin 
 
